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Abstract  
Background: The study aimed to validate previously discovered plasma biomarkers 
associated with AD, using a design based on imaging measures as surrogate for disease 
severity and assess their prognostic value in predicting conversion to dementia.  
Methods: Three multicentre cohorts of cognitively healthy elderly, mild cognitive 
impairment (MCI) and AD participants with standardised clinical assessments and structural 
neuroimaging measures were used. Twenty six candidate proteins were quantified in 1148 
subjects using multiplex (xMAP) assays.    
Results: Sixteen proteins correlated with disease severity, and cognitive decline. Strongest 
associations were in the MCI group with a panel of ten proteins predicting progression to AD 
(accuracy 87%, sensitivity 85%, and specificity 88%). 
Conclusions: We have identified ten plasma proteins strongly associated with disease 
severity and disease progression. Such markers may be useful for patient selection for clinical 
trials and, assessment of patients with pre-disease subjective memory complaints. 
Keywords: Plasma, Mild cognitive impairment, pathology, Alzheimer’s disease, biomarker, 
prediction and magnetic resonance imaging. 
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Introduction 
Alzheimer’s disease (AD) is the most common neurodegenerative disorder of the aging 
population; usually affecting people over the age of 65 years and resulting in progressive 
cognitive and functional decline. Detecting AD at the earliest possible stage is vital to enable 
trials of disease modification agents and considerable efforts are being invested in the 
identification and replication of biomarkers for this purpose.  
Such biomarkers currently include measures of tau and amyloid beta (Aβ) in cerebrospinal 
fluid (CSF), brain atrophy using magnetic resonance imaging (MRI) and measures of Aβ 
pathological load using positron emission tomography (PET). All these approaches are 
promising, although molecular imaging is currently a costly procedure available in relatively 
few centres and lumbar puncture is moderately invasive. Furthermore repeated measures are 
problematical in both cases. 
Blood (plasma) on the other hand is a more accessible bio-fluid suitable for repeated 
sampling. This led many groups including ours to investigate the potential of a diagnostic 
signal in blood. Using a case-control study design with a gel based approach (2-DGE & LC-
MS/MS) two proteins (complement factor H (CFH) and alpha-2-macroglobulin) were 
observed as potential markers of AD [1], both of which were subsequently replicated by 
independent groups [2,3]. In the same study we observed changes in serum amyloid P (SAP), 
complement C4 (CC4), and ceruloplasmin, all of which have been implicated in AD 
pathogenesis [4,5,6]. However, case-control studies are problematical when there is a long 
prodromal disease phase. In such instances a large proportion of apparently normal controls 
already harbour the disease processes and hence may already have a peripheral biomarker 
disease signature. In order to overcome the limitations of case-control design, we searched 
for proteins associated with surrogates of disease severity (hippocampal atrophy and clinical 
progression), and identified Clusterin as a marker associated with both these surrogate 
measures [7]. Building on this 'endophenotype' discovery approach we subsequently found 
transthyretin (TTR) and Apolipoprotein A1 (ApoA1) to be associated with faster declining 
AD subjects and increased plasma Apolipoprotein E (ApoE) levels related to increased Aβ 
burden in the brain [8,9].   
These studies, and those from other groups, have identified a set of proteins that might act as 
biomarkers relevant to AD. However such findings require replication, in large studies, 
ideally using samples drawn from more than one cohort source and using a platform that 
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enables multiplexing. We therefore developed multiplex panels using our discovery proteins 
together with additional putative candidate biomarkers that have been implicated in AD and 
neurodegeneration (supplementary table S1).  
The aims of the current study were 1) to validate a set of blood-based biomarkers in a large 
multicentre cohort with specified a priori outcome variables of the disease endophenotype 
measure of atrophy on MRI and of clinical severity and, 2) to determine the accuracy of a 
multiplexed panel of disease relevant biomarkers in predicting conversion of mild cognitive 
impairment to dementia in a defined time period.   
Methods 
Subjects and clinical classification 
Plasma samples from AD, (mild cognitively impaired subjects (MCI) and elderly non-
demented controls were selected from three independent studies. AddNeuroMed (ANM) a 
multi-center European study,[10] Kings Health Partners-Dementia Case Register (KHP-
DCR) a UK clinic and population based study and Genetics AD Association (GenADA) a 
multisite case–control longitudinal study based in Canada [11]. The diagnosis of probable 
AD was made according to Diagnostic and Statistical Manual for Mental Diagnosis (DSM-
IV) and National Institute of Neurological, Communicative Disorders and Stroke- 
Alzheimer’s disease and Related Disorders Association (NINCDS-ADRDA) criteria. MCI 
was defined according to Petersen criteria [12]. Standardized clinical assessment included the 
Mini-Mental State Examination (MMSE) for cognition and for global levels of severity the 
Clinical Dementia Rating (CDR) (ANM and KHP-DCR only). The human biological samples 
were sourced ethically and their research use was in accord with the terms of the informed 
consents. 
In total we examined plasma samples from 1148 subjects - 476 with AD, 220 with MCI and 
452 elderly controls with no dementia (Table 1). The APOE SNPs rs429358 and rs7412 were 
genotyped using Taqman SNP genotyping assays (determined by allelic discrimination assays 
based on fluorogenic 5′ nuclease activity) and the allele inferred.   
Cognitive decline  
Cognitive decline, as determined by the slope of change in cognition, was calculated for a 
subset of AD subjects (n=342) who had a minimum of three separate MMSE assessments. 
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The rate of cognitive decline was calculated separately for ANM since it had a different 
following up interval (every 3 months over one year) in comparison to DCR and GenADA, 
which were followed up yearly over a period of at least three years. Linear mixed effect 
models were generated using the package ‘nlme’ in R. We estimated the rate of change using 
a multi-level linear model with random intercepts and random slopes adjusted for subject and 
centre level clustering. Covariates including age at baseline, gender, apolipoprotein (APOE) 
ε4 allele presence, and years of education were investigated for their effect on the rate of 
decline. Age at baseline and years of education had a significant effect on the rate (p-
value<0.05) and thus were included as fixed effects in the final model. The slope coefficient 
obtained from the final model for each sample was then used as a rate of cognitive change, 
defined as the change in MMSE score per year. 
Magnetic Resonance Imaging (MRI) 
High resolution sagittal 3D T1-weighted MPRAGE volume (voxel size 1.1 × 1.1 × 1.2 mm³) 
and axial proton density/T2-weighted fast spin echo images were acquired on 1.5T MRI 
scanners for 476 of the subjects (179 control, 123 MCI and 174 AD) as previously 
reported.[13]  The MPRAGE volume was acquired using a custom pulse sequence 
specifically designed for the ADNI study to ensure compatibility across scanners [14]. Full 
brain and skull coverage was required for all MR images according to previously published 
quality control criteria [13,15]. Image analysis was carried out using the Freesurfer image 
analysis pipeline (version 5.1.0) to produce regional cortical thickness and subcortical 
volumetric measures as previously described [16,17]. This segmentation approach has been 
previously used for analysis in imaging-proteomic studies [18] and AD biomarker discovery 
[16]. All volumetric measures from each subject were normalized by the subject’s 
intracranial volume while cortical thickness measures were used in their raw form [19]. 
Measures of hippocampal volume, entorhinal cortex volume and ventricular volume were 
chosen as MRI endophenotypes of AD. For evaluation of hippocampal atrophy the MRI data 
was stratified into high and low atrophy for the MCI group based on their median volumetric 
measures.  
Immunoassay – Luminex measurement 
All candidate proteins were measured using multiplex bead assays (Luminex xMAP) 
(Supplementary S1) incorporated in 7 MILLIPLEX MAP panels (Supplementary S2 and S3) 
run on the Luminex 200 instrument according to manufacturer’s instructions. 
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Data Pre-processing  
Prior to statistical analysis, we examined the performance of each assay using quality checks 
(QC) as outlined in the supplementary material. Median fluorescent intensity (MFI) was 
measured using xPONENT 3.1 (Luminex Corporation) and exported into Sigma plot (Systat 
Software; version 12) for estimation of protein concentrations using a 5-parameter logistic fit. 
Briefly, all analytes that passed QC checks based on the following 4 criteria (standard curve 
linearity, intra-assay coefficient of variation, inter-assay CV for reference sample and 
percentage of missing data; Supplementary material S3) were taken forward for further 
analysis.   
Statistical analysis 
Univariate analysis 
Univariate statistical analysis was performed in SPSS 20 (IBM). All raw MFI measures were 
log10 transformed to achieve normal distribution. Covariates including age, gender, plasma 
storage duration (days) and centre were investigated. We found that the majority of proteins 
were significantly affected by these covariates and therefore values were adjusted using a 
generalized linear regression model (GLM). All subsequent analysis was performed on the 
GLM adjusted data. Partial correlation (adjusting for APOE genotype) analysis was 
performed to examine associations with either structural MRI brain imaging or cognition 
assessments. Correlations were performed separately within diagnostic groups due to the 
discrete nature of the clinical scores across all groups. The proteins were also analysed 
individually for their association with disease phenotypes: disease status (AD vs. control) via 
ANCOVA (adjusting for APOE genotype). Multiple linear regressions were performed to test 
how combinations of proteins could predict hippocampal volume.  
Classification analysis 
Class prediction and attribute selection was performed using WEKA (University of Waikato). 
Naive Bayes Simple algorithm was used with default settings unless stated otherwise. The 
dataset was randomly split into 75% train and 25% test for the MCI-converter (MCIc) and 
MCI-non-converter (MCInc) groups. Attribute selection was performed using the Classifier 
Subset Evaluator with best first search method on the training data. Five iterations of attribute 
selection were performed ranked by times observed. Proteins seen >3 or more times were 
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taken forward as predictor variables (Table 3). Any class imbalance was overcome by 
applying the Synthetic Minority Oversampling Technique (SMOTE) in WEKA.    
Cut-off point analysis 
Untransformed protein concentrations on the full dataset (n=169 MCIc and n=51 MCInc) were 
binarised at different cut-off points using the upper and lower quartile ranges and the 
percentile rank.  A minimum of three cut-off concentrations were tested per protein. Logistic 
regression analysis was performed on individual cut-off concentrations and selected based on 
their accuracy of predicting conversion.      
Results  
Study Participants 
The demographic and clinical characteristics of participants from the three cohorts are 
presented in Table 1. The AD group were marginally, but significantly older than controls 
(AD: mean 77 yrs, Controls: 75 yrs, p=0.01). The frequency of the APOEε4 allele was higher 
in MCI and AD groups than controls.  
Plasma proteins and brain atrophy 
Of the 26 proteins measured only two proteins were found to be significantly different 
between AD and controls (ApoE: F=6.5, p<0.001; CFH: F=6.1, p<0.001). However, using 
partial correlation, and adjusting for APOE, we identified a number of plasma proteins that 
were significantly associated with atrophy using MRI measures of one or more of the brain 
regions; hippocampus, entorhinal cortex, ventricles and whole brain volume in the disease 
groups (tables 2a and b). Controlling for multiple testing, only Clusterin (MCI group: 
p<0.001) and ApoE (AD group: p=0.0014) remained significant.   
We then set out to identify proteins that collectively would predict disease progression, as 
represented by the surrogate of hippocampal atrophy, in a pre-disease group of MCI. Using 
multiple linear regression analysis, we identified 6 proteins (Clusterin, RANTES, NSE, TTR, 
VCAM-1, and SAP) that predicted 19.5% (p=0.006) of hippocampal volume in subjects with 
MCI. We observed a different combination of proteins associated with atrophy in the AD 
group. Using linear regression analysis, 7 proteins (APOA1, A1AT, ApoC3, BDNF, AB40, 
PAI-1, and NSE) in the AD group were able to predict 11.9% (p=0.039) of hippocampal 
volume.  
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In summary we found an association of Clusterin with greater atrophy, and a trend towards 
reduced RANTES, NSE and TTR levels in the MCI group. In the AD group A1AT, NSE, 
ApoC3, ApoA1, ApoE, and BDNF plasma levels were increased in subjects with increased 
atrophy.  
Plasma proteins clinical cognition and cognitive decline 
We examined the relationship between these proteins and disease severity as measured by 
cognition at the time of sampling and by rate of change in cognition. In the MCI group at the 
point of sampling, both ApoE and CRP negatively correlated with MMSE (ApoE: r=-0.15, 
p=0.001; CRP: r=-0.186, p=0.007). 
In the AD group at the point of sampling ApoE, CFH, NCAM, AB40, A1AcidG, and 
Clusterin were all negatively correlated with MMSE (ApoE: r=-0.150, p=0.001; CFH: r=-
0.104, p=0.026; NCAM: r=-0.114, p=0.014; AB40: r=-0.161, p=0.001; A1AcidG: r=-0.135, 
p=0.004; Clusterin: r=-0.135, p=0.004).  
Furthermore, we assessed the association of the proteins with longitudinal prospective 
MMSE change in the AD group. Three proteins, NCAM, sRAGE and ICAM, were 
significantly associated with the rate of change in cognition; NCAM and sRAGE were both 
negatively correlated (NCAM: r=-0.129, p=0.0018; sRAGE: r=-0.125, p=0.029) whereas 
ICAM was positively correlated (ICAM: r=0.108, p=0.047).  
Protein biomarkers to predict disease conversion: MCI to AD 
In summary we confirmed that a number of proteins, previously identified as putative 
markers of AD, correlated with disease severity, measured by MRI or severity of cognitive 
impairment not only in disease but in the pre-disease state of MCI. We therefore reasoned 
that if these proteins are reflecting pathological load that they may also be markers predictive 
of conversion from pre-disease states such as MCI to clinical dementia.  
To test this, we used a machine learning approach (Naive Bayes Simple) with feature 
selection on a training dataset (Figure 1) and then applied this to a test set. The average time 
of conversion of MCI to AD was approximately one year (375 days, SD=23 days). Ten 
proteins (TTR, Clusterin, Cystatin C, A1AcidG, ICAM1, CC4, PEDF, A1AT, RANTES, 
ApoC3) plus APOE genotype had the greatest predictive power (Table 3). The receiver 
operating curve characteristic (ROC) for the independent test set is shown in Figure 2a. The 
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ROC area under the curve (AUC) (Table 4a) of the test set was 0.78 (protein only) and 0.84 
(protein + APOE genotype). To test the accuracy, we investigated 3 different sensitivity cut-
off points at 30%, 50% and 85%. The optimal accuracy was observed at the 85% sensitivity 
with the test achieving an accuracy of 87% with a specificity of 88%. 
We then investigated whether combining structural MRI data with these 10 proteins observed 
in the MCI conversion data would improve classiﬁcation accuracy. MRI brain measures for a 
subset of subjects were combined with the protein data and the Naive Bayes algorithm was 
applied. In this smaller dataset the proteins alone performed very well when tested at the 3 
different sensitivity cut-offs (Cut-off: accuracy; 30%: 83.3%, 50%: 80.6%, 85%: 69.4%). The 
addition of MRI data only marginally improved the accuracy at 2 cut-off points (Cut-off: 
accuracy 30%: 86%; 50%: 83%) but reduced it at the 85% sensitivity cut-off to 64% (Figure 
2b and Table 4b).  
Concentration cut-offs points for proteins predicting MCI to AD 
Individual protein cut-off values were derived for the 10 proteins identified by feature 
selection in the MCI conversion model. Values predictive of conversion to AD were; 
ApoC3< 105.5ug/ml, TTR< 222 ug/ml, A1AT< 9.5ug/ml, PEDF> 10.7ug/ml, CC4> 
78.5ug/ml, ICAM-1< 99.72ng/ml, RANTES< 33.8ng/ml, A1AcidG> 768.3ug/ml, Cystatin 
C< 3.21ug/ml, Clusterin> 402ug/ml. Logistic regression was applied to test the 10 protein 
cut-off concentrations and APOE genotype, the overall model accuracy was 94.9%, with a 
sensitivity 73.6%, and specificity of 94.9% when using the full dataset.   
Discussion  
Previous studies by our group using data-driven pan-proteomic approaches have identified a 
number of proteins as diagnostic [1] progression [7,20] and markers of disease severity [18]. 
The advent of high throughput multiplex platforms facilitates the replication of such findings 
and raises the potential of high throughput multiplexed markers for use in clinical practice 
and in clinical trials [21,22,23]. In this study we have used a multiplex antibody capture 
platform to determine if our putative biomarkers are associated with early disease stages and 
might have value as prognostic markers. Using MRI as a surrogate of disease pathology we 
identified a number of proteins that were associated with atrophy either early in the disease 
process (MCI) or in established dementia.    
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This approach of using MRI as a proxy for in vivo pathology has previously been shown to be 
useful in biomarker discovery, including in our study identifying Clusterin as a putative 
marker of disease [7]. In the current study we identified RANTES, NSE and transthyretin, in 
addition to Clusterin, to be associated with cortical atrophy in the MCI group, with Clusterin 
showing the strongest correlation with all brain regions assessed. The other proteins have 
previously been implicated in AD. RANTES, also known as chemokine ligand 5 (CCL5), is a 
protein known to have an active role in recruiting leukocytes into inflammatory sites. We find 
a negative association between RANTES and ventricular volume, suggesting a decreased 
level with increased disease related pathology; the opposite to previous reports in 
neurodegeneration [24,25,26]. One possible explanation might be that since we observe 
RANTES association with atrophy only in MCI and not in AD, perhaps a decrease early in 
disease process is followed by an increase. Similar findings have been previously reported for 
other proteins [27] and we also observe a similar relationship with neuron-specific enolase 
(NSE), the second protein we observe in association with brain atrophy. This protein is 
thought to be an indicator of acute neuronal damage [28,29] and has been associated with AD 
in some but not all previous studies [30,31]. We find a positive association between NSE and 
volume of hippocampus and whole brain in MCI subjects, but in the AD group we find a 
positive association instead with ventricular volume. This inverse relationship with atrophy in 
pre-disease and then positive correlation with atrophy in disease suggests to us, that like 
RANTES, NSE might be decreased in early disease stages (i.e. MCI) with a rebound 
elevation in established AD.  
In established AD we observe a different set of proteins associated with disease severity as 
measured by atrophy on MRI, in line with this concept of disease phase specific biomarkers. 
A number of these belong to the group of apolipoproteins (ApoE, ApoC3 and ApoA1). We 
found these proteins were negatively associated with hippocampal, entorhinal cortical and 
whole brain volumes. The roles of apolipoproteins in neurodegenerative disorders have been 
studied extensively since the discovery that APOE was a major susceptibility gene for AD 
[32,33]. In the peripheral system, ApoE serves in the transport of triglycerides, phospholipids 
and cholesterol into cells [34]. The literature on ApoE is conflicting with some groups 
reporting lower ApoE in AD [35,36], with others showing increased levels [37,38]. ApoE 
plasma measurements derived from this study have been recently published and are in 
agreement with the findings from the North American Alzheimer's Disease Neuroimaging 
Initiative, which reports an APOE genotype effect [39].  
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Our present findings suggest that we have identified a panel of plasma biomarkers, associated 
with neuroimaging measures of disease, which may serve as readily accessible markers of 
early disease severity. Moreover, we identify a set of ten protein biomarkers that can 
prospectively predict disease conversion from MCI to AD within a year of blood sampling. 
These results are supported by other evidence that plasma proteins can have a role in early 
disease detection, with inflammatory proteins in particular being identified as possible 
predictors of conversion from MCI [23,40]. It is important to note that when attempting to 
compare such biomarker studies, the lack of standardised reagents, particularly antibodies 
may result in different outcomes reflecting technical differences between analytical platforms 
more than disease biology. Therefore our ability to replicate these proteins using an 
orthoganol approach (mass spectrometry in discovery, multiplexed immune capture in 
replication), makes these findings particularly powerful and robust. Moreover, combining 
MRI with protein measures did not improve predictive power in contrast to previous studies 
where CSF marker performance was improved in combination with MRI [41].  
Although this study is built on findings from previous discovery-led and replicated findings, 
further replication will be needed. Ideally such replication should be in large, longitudinal, 
population based cohorts. Such as study would be able to address potential confounds of the 
data reported in this study including site-specific effects and representativeness of the 
cohorts. Further studies will also be needed to address specificity. The markers we have 
identified are often altered in other disease areas – inflammation, cardiovascular, respiratory, 
dental and others – and it will be important to distinguish the relative overlap and 
confounding by these diseases. However, although the protein participants in the panel we 
have identified are often altered in other disease states, these diseases are all different and 
therefore the panel itself may show specificity even if the participants do not. This remains to 
be determined. It also remains to be seen whether the panel we have identified is specific to 
AD or shows biomarker utility in relation to other dementia syndromes. Although we used an 
assessment protocol that previously we have shown is highly accurate in distinguishing AD 
from other dementias based on post-mortem confirmation, it will be interesting in due course 
to correlate the behavior of our panel to specific markers of dementia pathology such as 
biochemical or imaging measures of Abeta and tau.  
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In summary, using a multiplexing approach we have validated a plasma protein panel as a 
marker reflecting disease severity and for predicting disease progression within three large 
multicentre cohorts. Such a marker set may have considerable value in triaging patients with 
early memory disorders, to other more invasive approaches such as molecular markers in 
CSF and PET imaging, in clinical trials and possibly in clinical practice. 
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Table 1. Subject demographics: Abbreviations: AD, Alzheimer’s disease; APOE, Apolipoprotein E; 
CDR, Clinical dementia rating; GDS, Global Deterioration Scale; MCI, mild cognitive impairment; 
MMSE, mini mental state examination. Mean (±S.D, Range), ANOVA was performed and if 
significant a Tukey’s post-hoc comparison was carried out. * Sig. Across all 3 groups, # Control 
compared to AD.   
Table 2. Proteins identified as significantly associated with structural brain MRI measures in the (a) 
MCI group and (b) AD group. * Pearson’s correlation coefficient; n/a = no significant association 
observed     
Figure 1. Feature selection workflow used to select the best attributes for MCIc classification. 
Table 3. Proteins observed in the feature selection. Ranked according to the number of times a protein 
was observed in the feature selection. Proteins highlighted in bold were taken forward as the 
predictors for MCI conversion.  
Figure 2. Receiver operating characteristic (ROC) curves obtained for the test set for (a) three models 
(Proteins only, Proteins + APOE and APOE only) from the full MCIc and MCInc dataset and (b) for 
the test set for three models (Proteins only, Proteins + APOE +MRI and MRI only) in the subset with 
protein plus MRI imaging data.    
Table 4. Characteristics of the ROC curve for (a) the full dataset without MRI and (b) ROC curve 
characteristics for the subset with MRI imaging data. Three different sensitivity cut-off points were 
investigated. Sensitivity (SN), speciﬁcity (SP), positive predictive value (PPV), negative predictive 
value (NPV) Accuracy (ACC) and ROC area under curve (AUC) for the protein and APOE 
classiﬁers. 
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Table 1 
 Control MCI AD Sig. 
  MCI-NC MCI-C   
N 452 169 51 476  
Age (yrs) 75.6 (±6.3, 
53-93) 
76.3 (±5.7, 
65-90) 
76.2 (±6.9, 
56-89) 
77.0 (±6.4, 
58-96) 
P=0.012# 
Sex (%, Female) 55.6% 50.1% 49.1% 49.4% P=0.277 
APOE genotype (%, 
e4+) 
28% 35% 55% 59% P<0.001# 
MMSE 29.0 (±1.2, 
22-30) 
26.9 (±2.9, 
0-30) 
26.3 (±2.1, 
18-30) 
20·8 (±5·4, 
0-30) 
P<0·001* 
CDR (Sum of 
Boxes) 
0·18 (±0·4, 
0-3) 
1·82 (±0·9, 
0-4·5) 
2·41 (±0·9, 
0·5-5) 
4·04 (±3·2, 
0-20) 
P<0·001* 
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Table 2 
(a) 
MCI group 
(b) 
AD group 
MRI brain region Protein 
Correlation 
coefficient* 
Significance 
(2-tailed) 
df MRI brain region Protein 
Correlation 
coefficient* 
Significance 
(2-tailed) 
df 
Ventricular volume 
Clusterin 
RANTES 
0.23 
-0.19 
0.01 
0.03 
115 
116 Ventricular volume 
A1AT 
NSE 
0.24 
0.16 
0.01 
0.03 
119 
169 
Mean hippocampal 
volume 
Clusterin 
NSE 
-0.38 
0.22 
0.00 
0.02 
115 
116 Mean hippocampal 
volume 
BDNF 
ApoC3 
ApoA1 
ApoE 
-0.21 
-0.18 
-0.15 
-0.15 
0.02 
0.02 
0.04 
0.05 
123 
168 
169 
169 
Right Entorhinal thickness Clusterin -0.22 0.02 115 Right Entorhinal thickness n/a n/a n/a n/a 
Left Entorhinal thickness Prealbumin -0.20 0.04 109 Left Entorhinal thickness n/a n/a n/a n/a 
Mean Entorhinal 
volume n/a n/a n/a n/a 
Mean Entorhinal 
volume 
ApoC3 
ApoE 
-0.20 
-0.18 
0.01 
0.02 
168 
169 
Mean Entorhinal 
Thickness n/a n/a n/a n/a 
Mean Entorhinal 
Thickness 
ApoC3 
ApoA1 
ApoE 
Prealbumin 
-0.22 
-0.21 
-0.2 
-0.15 
0.01 
0.01 
0.01 
0.05 
168 
169 
169 
158 
Whole Brain Volume 
Clusterin 
NSE 
RANTES 
-0.25 
0.21 
0.19 
0.01 
0.02 
0.04 
118 
119 
119 Whole Brain Volume 
ApoE 
ApoA1 
AB40 
-0.19 
-0.19 
0.17 
0.02 
0.02 
0.04 
145 
145 
141 
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Total samples 
N=220
(MCI-C=51; 
MCI-NC=169)
WEKA: attribute Selection
Attribute evaluator: Classifier subset evaluator, 
Classifier: Naive Bayes Simple 
Search Method: Best first
Attribute evaluation method: Cross validation 10x 
Optimised feature selection 
performed in the training.
5X iterations performed 
Train 75% 25% Test
Optimised attributes selected
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Table 3 
Protein No. Times 
observed in feature 
selection 
Protein No. Times observed in 
feature selection 
Transthyretin 5 CathepsinD 1 
Clusterin 4 ApoE 1 
Cystatin C 4 SAP 0 
A1AcidG 4 Ceruloplasmin 0 
ICAM1 4 NCAM 0 
CC4 4 NSE 0 
PEDF 4 VCAM1 0 
A1AT 4 A2M 0 
APOE genotype 3 B2M 0 
RANTES 3 BDNF 0 
ApoC3 3 CFH 0 
PAI-1 2 ApoA1 0 
CRP 2 Ab40 0 
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a 
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Table 4 
 
 
 
 
 
 
(a) ROC characteristics without MRI (b) ROC characteristics with MRI 
Classification 
model 
Sensitivity 
cut-off % 
SN 
% 
SP % PPV % NPV % ACC % ROC 
(AUC) 
Classification 
model 
Sensitivity 
cut-off % 
SN 
% 
SP % PPV 
% 
NPV 
% 
ACC 
% 
ROC 
(AUC) 
Protein + APOE 30 30.8 92.9 57.1 81.3 87.2 0.84 Protein + 
APOE + MRI 
30 33.3 96.7 66.7 87.9 86.1 0.75 
Protein only 30 30.8 92.9 57.1 81.3 87.2 0.78 Protein only 30 33.3 93.3 50.0 87.5 83.3 0.82 
Protein + APOE 50 53.9 88.1 58.3 86.1 80.0 0.84 MRI only 30 33.3 80.0 25.0 85.7 72.2 0.54 
Protein only 50 43.8 84.6 53.9 78.6 72.7 0.78 Protein + 
APOE + MRI 
50 50.0 90.0 50.0 90.0 83.3 0.75 
Protein + APOE 85 84.6 88.1 68.8 94.9 87.2 0.84 Protein only 50 50.0 86.7 42.9 89.7 80.6 0.82 
Protein only 85 84.6 71.4 47.8 93.8 74.5 0.78 MRI only 50 50.0 63.3 21.3 86.4 61.1 0.54 
        Protein + 
APOE + MRI 
85 83.3 60.0 29.4 94.7 63.9 0.75 
        Protein only 85 83.3 66.7 33.3 95.2 69.4 0.82 
        MRI only 85 83.3 13.3 16.1 80.0 25.0 0.54 
